4//SEC Filing
PAKOLA STEVE 4
Accession 0001562180-22-000159
CIK 0001590877other
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 9:05 PM ET
Size
11.1 KB
Accession
0001562180-22-000159
Insider Transaction Report
Form 4
REGENXBIO Inc.RGNX
PAKOLA STEVE
Chief Medical Officer
Transactions
- Sale
Common Stock
2022-01-03$33.75/sh−1,598$53,933→ 8,250 total - Award
Stock Option (Right to Buy)
2022-01-03+42,500→ 42,500 totalExercise: $34.31Exp: 2032-01-03→ Common Stock (42,500 underlying) - Tax Payment
Common Stock
2022-01-01$32.70/sh−1,152$37,670→ 9,848 total - Award
Common Stock
2022-01-03+8,900→ 17,150 total
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $33.72 to $33.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer.
- [F4]25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer.
Documents
Issuer
REGENXBIO Inc.
CIK 0001590877
Entity typeother
Related Parties
1- filerCIK 0001700659
Filing Metadata
- Form type
- 4
- Filed
- Jan 3, 7:00 PM ET
- Accepted
- Jan 4, 9:05 PM ET
- Size
- 11.1 KB